Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12177691,K(i),"DPC423, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, is a synthetic, orally bioavailable, competitive, and selective inhibitor of human coagulation factor Xa (K(i) [nM]: factor Xa, 0.15; trypsin, 60; thrombin, 6000; plasma kallikrein, 61; activated protein C, 1800; factor IXa, 2200; factor VIIa, >15,000; chymotrypsin, >17,000; urokinase, >19,000; plasmin, >35,000; tissue plasminogen activator, >45,000; complement factor I, 44,000 [IC(50)]).","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,0.15,7185,DB00013,Urokinase
,12177691,K(i),"DPC423, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, is a synthetic, orally bioavailable, competitive, and selective inhibitor of human coagulation factor Xa (K(i) [nM]: factor Xa, 0.15; trypsin, 60; thrombin, 6000; plasma kallikrein, 61; activated protein C, 1800; factor IXa, 2200; factor VIIa, >15,000; chymotrypsin, >17,000; urokinase, >19,000; plasmin, >35,000; tissue plasminogen activator, >45,000; complement factor I, 44,000 [IC(50)]).","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,44,7186,DB00013,Urokinase
,12177691,oral bioavailability,"In dogs, DPC423 had a good pharmacokinetic profile with an oral bioavailability of 57%, a plasma clearance of 0.24 L/kg/h, and a plasma half-life of 7.5 h.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),%,57,7187,DB00013,Urokinase
,12177691,plasma clearance,"In dogs, DPC423 had a good pharmacokinetic profile with an oral bioavailability of 57%, a plasma clearance of 0.24 L/kg/h, and a plasma half-life of 7.5 h.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),[l] / [h·kg],0.24,7188,DB00013,Urokinase
,12177691,plasma half-life,"In dogs, DPC423 had a good pharmacokinetic profile with an oral bioavailability of 57%, a plasma clearance of 0.24 L/kg/h, and a plasma half-life of 7.5 h.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),h,7.5,7189,DB00013,Urokinase
,12177691,IC(50),"In rabbit and rat models of arteriovenous shunt thrombosis, DPC423 was an effective antithrombotic agent with an IC(50) of 150 and 470 nM, respectively.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,150,7190,DB00013,Urokinase
,12177691,IC(50),"In rabbit and rat models of arteriovenous shunt thrombosis, DPC423 was an effective antithrombotic agent with an IC(50) of 150 and 470 nM, respectively.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,470,7191,DB00013,Urokinase
,3612530,alpha T1/2,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),min,3.2 to 3.9,9709,DB00013,Urokinase
,3612530,beta T1/2,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),min,15 to 16,9710,DB00013,Urokinase
,3612530,volume of the central compartment,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),ml,170 to 200,9711,DB00013,Urokinase
,3612530,total volume of distribution,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),ml,660 to 910,9712,DB00013,Urokinase
,3612530,plasma clearance,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),[ml] / [min],18 to 22,9713,DB00013,Urokinase
,3612530,T1/2,"Steady-state plasma levels of scu-PA during continuous i.v. infusion were proportional to the dose given, whereas the initial postinfusion disappearance rate of scu-PA from plasma was comparable to that after bolus injection (T1/2 of 5 to 6 min).",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),min,5 to 6,9714,DB00013,Urokinase
,10876808,half life,"However, due to its extremely short half life (approximately 5 min), it is necessary to administer this drug by high-dosage infusion, increasing the possibility of systemic bleeding.","[Research and development of novel modified tissue-type plasminogen activator (t-PA), pamiteplase]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10876808/),min,5,13835,DB00013,Urokinase
,10602568,total clearance,"The total clearance of urokinase (179 +/- 55 ml/min) is about half that of saruplase (406 +/- 154 ml/min), and the mean residence time of urokinase (59.1 +/- 22.5 minutes) is nearly twice that of saruplase (28.3 +/- 7.8 minutes), which results in a slower elimination of urokinase from plasma.",Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602568/),[ml] / [min],179,24101,DB00013,Urokinase
,10602568,total clearance,"The total clearance of urokinase (179 +/- 55 ml/min) is about half that of saruplase (406 +/- 154 ml/min), and the mean residence time of urokinase (59.1 +/- 22.5 minutes) is nearly twice that of saruplase (28.3 +/- 7.8 minutes), which results in a slower elimination of urokinase from plasma.",Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602568/),[ml] / [min],406,24102,DB00013,Urokinase
,10602568,mean residence time,"The total clearance of urokinase (179 +/- 55 ml/min) is about half that of saruplase (406 +/- 154 ml/min), and the mean residence time of urokinase (59.1 +/- 22.5 minutes) is nearly twice that of saruplase (28.3 +/- 7.8 minutes), which results in a slower elimination of urokinase from plasma.",Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602568/),min,59.1,24103,DB00013,Urokinase
,10602568,mean residence time,"The total clearance of urokinase (179 +/- 55 ml/min) is about half that of saruplase (406 +/- 154 ml/min), and the mean residence time of urokinase (59.1 +/- 22.5 minutes) is nearly twice that of saruplase (28.3 +/- 7.8 minutes), which results in a slower elimination of urokinase from plasma.",Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602568/),min,28.3,24104,DB00013,Urokinase
,23411397,half-life,Extensive in vivo PK studies in NOD-SCID mice revealed a half-life of nearly 5h and peak concentration of 5 μM.,"Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411397/),h,5,24607,DB00013,Urokinase
,23411397,peak concentration,Extensive in vivo PK studies in NOD-SCID mice revealed a half-life of nearly 5h and peak concentration of 5 μM.,"Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411397/),μM,5,24608,DB00013,Urokinase
,8269200,initial half-life,K1K2Pu disappeared from the plasma with an initial half-life of 9 min and a clearance of approximately 50 ml/min.,"Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269200/),min,9,51617,DB00013,Urokinase
,8269200,clearance,K1K2Pu disappeared from the plasma with an initial half-life of 9 min and a clearance of approximately 50 ml/min.,"Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269200/),[ml] / [min],50,51618,DB00013,Urokinase
,8165632,recoveries,"The rscu-PA-32k moieties were expressed in High Five Trichoplasiani cells, and purified to homogeneity from the conditioned cell culture medium, with recoveries of 0.8 to 3.7 mg/l.",Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165632/),[mg] / [l],0.8 to 3.7,58443,DB00013,Urokinase
,8165632,plasma clearance,"Following bolus injection in hamsters, all rscu-PA-32k moieties had a comparably rapid plasma clearance (1.3 to 2.7 ml/min), as a result of a short initial half-life (1.4 to 2.5 min).",Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165632/),[ml] / [min],1.3 to 2.7,58444,DB00013,Urokinase
,8165632,initial half-life,"Following bolus injection in hamsters, all rscu-PA-32k moieties had a comparably rapid plasma clearance (1.3 to 2.7 ml/min), as a result of a short initial half-life (1.4 to 2.5 min).",Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165632/),min,1.4 to 2.5,58445,DB00013,Urokinase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,720,64541,DB00013,Urokinase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,45,64542,DB00013,Urokinase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,210,64543,DB00013,Urokinase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,49,64544,DB00013,Urokinase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,310,64545,DB00013,Urokinase
,1909220,l,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,49,64546,DB00013,Urokinase
,1909220,l,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,90,64547,DB00013,Urokinase
,12376503,maximum plasma concentrations,"The maximum plasma concentrations of EGCG, EGC, and EC in the three repeated experiments with green tea were 77.9 +/- 22.2, 223.4 +/- 35.2, and 124.03 +/- 7.86 ng/ml, respectively, and the corresponding AUC values were 508.2 +/- 227, 945.4 +/- 438.4, and 529.5 +/- 244.4 ng x h x ml(-1), respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),[ng] / [ml],77.9,82599,DB00013,Urokinase
,12376503,maximum plasma concentrations,"The maximum plasma concentrations of EGCG, EGC, and EC in the three repeated experiments with green tea were 77.9 +/- 22.2, 223.4 +/- 35.2, and 124.03 +/- 7.86 ng/ml, respectively, and the corresponding AUC values were 508.2 +/- 227, 945.4 +/- 438.4, and 529.5 +/- 244.4 ng x h x ml(-1), respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),[ng] / [ml],223.4,82600,DB00013,Urokinase
,12376503,maximum plasma concentrations,"The maximum plasma concentrations of EGCG, EGC, and EC in the three repeated experiments with green tea were 77.9 +/- 22.2, 223.4 +/- 35.2, and 124.03 +/- 7.86 ng/ml, respectively, and the corresponding AUC values were 508.2 +/- 227, 945.4 +/- 438.4, and 529.5 +/- 244.4 ng x h x ml(-1), respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),[ng] / [ml],124.03,82601,DB00013,Urokinase
,12376503,AUC,"The maximum plasma concentrations of EGCG, EGC, and EC in the three repeated experiments with green tea were 77.9 +/- 22.2, 223.4 +/- 35.2, and 124.03 +/- 7.86 ng/ml, respectively, and the corresponding AUC values were 508.2 +/- 227, 945.4 +/- 438.4, and 529.5 +/- 244.4 ng x h x ml(-1), respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),[h·ng] / [ml],508.2,82602,DB00013,Urokinase
,12376503,AUC,"The maximum plasma concentrations of EGCG, EGC, and EC in the three repeated experiments with green tea were 77.9 +/- 22.2, 223.4 +/- 35.2, and 124.03 +/- 7.86 ng/ml, respectively, and the corresponding AUC values were 508.2 +/- 227, 945.4 +/- 438.4, and 529.5 +/- 244.4 ng x h x ml(-1), respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),[h·ng] / [ml],945.4,82603,DB00013,Urokinase
,12376503,AUC,"The maximum plasma concentrations of EGCG, EGC, and EC in the three repeated experiments with green tea were 77.9 +/- 22.2, 223.4 +/- 35.2, and 124.03 +/- 7.86 ng/ml, respectively, and the corresponding AUC values were 508.2 +/- 227, 945.4 +/- 438.4, and 529.5 +/- 244.4 ng x h x ml(-1), respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),[h·ng] / [ml],529.5,82604,DB00013,Urokinase
,12376503,time needed to reach the peak concentrations,The time needed to reach the peak concentrations was in the range of 1.3-1.6 h.,Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),h,1.3-1.6,82605,DB00013,Urokinase
,12376503,elimination half-lives,"The elimination half-lives were 3.4 +/- 0.3, 1.7 +/- 0.4, and 2.0 +/- 0.4 h, respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),h,3.4,82606,DB00013,Urokinase
,12376503,elimination half-lives,"The elimination half-lives were 3.4 +/- 0.3, 1.7 +/- 0.4, and 2.0 +/- 0.4 h, respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),h,1.7,82607,DB00013,Urokinase
,12376503,elimination half-lives,"The elimination half-lives were 3.4 +/- 0.3, 1.7 +/- 0.4, and 2.0 +/- 0.4 h, respectively.",Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),h,2.0,82608,DB00013,Urokinase
,12376503,half life,The plasma level of 4'-O-methyl EGC peaked at 1.7 +/- 0.5 h with a half life of 4.4 +/- 1.1 h.,Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376503/),h,4.4,82609,DB00013,Urokinase
,32108909,plasma half-life,"At a dose level of 20.6 mg kg-1, the antibody had a plasma half-life of 210 h.",Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32108909/),h,210,94029,DB00013,Urokinase
over,8236138,plasma half-life,"K2tu-PA, as t-PA has high affinity for fibrin and is activated by fibrin but has a longer plasma half-life (over 30 min).",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),min,30,113330,DB00013,Urokinase
,8236138,accretion,"The injection of the three increasing doses of rt-PA was followed by an accretion of 54.9 +/- 5.3 micrograms, 49.1 +/- 6.1 micrograms and 47.2 +/- 4.8 micrograms.",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),μg,54.9,113331,DB00013,Urokinase
,8236138,accretion,"The injection of the three increasing doses of rt-PA was followed by an accretion of 54.9 +/- 5.3 micrograms, 49.1 +/- 6.1 micrograms and 47.2 +/- 4.8 micrograms.",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),μg,49.1,113332,DB00013,Urokinase
,8236138,accretion,"The injection of the three increasing doses of rt-PA was followed by an accretion of 54.9 +/- 5.3 micrograms, 49.1 +/- 6.1 micrograms and 47.2 +/- 4.8 micrograms.",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),μg,47.2,113333,DB00013,Urokinase
,21302035,t1/2,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),h,1.5,117383,DB00013,Urokinase
,21302035,t1/2,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),h,1.3,117384,DB00013,Urokinase
,21302035,t1/2,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),h,1.2,117385,DB00013,Urokinase
,21302035,AUC0-t,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],1.0,117386,DB00013,Urokinase
,21302035,AUC0-t,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],2.1,117387,DB00013,Urokinase
,21302035,AUC0-t,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],5.6,117388,DB00013,Urokinase
,21302035,AUC0-∞,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],1.1,117389,DB00013,Urokinase
,21302035,AUC0-∞,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],2.1,117390,DB00013,Urokinase
,21302035,AUC0-∞,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],5.8,117391,DB00013,Urokinase
,1771627,alpha,The clearance of the parent material was biphasic with average alpha and beta half-lives of 1.7 min and 16.7 min respectively.,igh sialic acid content slows prourokinase turnover in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771627/),min,1.7,131694,DB00013,Urokinase
,1771627,beta half-lives,The clearance of the parent material was biphasic with average alpha and beta half-lives of 1.7 min and 16.7 min respectively.,igh sialic acid content slows prourokinase turnover in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771627/),min,16.7,131695,DB00013,Urokinase
,1771627,AUCs,Species with 60% or 90% removal of sialate were much more rapidly cleared from the circulation respectively yielding AUCs equal to 56% and 41% of that observed with the parent material.,igh sialic acid content slows prourokinase turnover in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771627/),,56,131696,DB00013,Urokinase
,1906642,half-life,"Using a 3-compartment model, in group I 98% of urokinase antigen were cleared with a half-life of 60.8 min.",Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906642/),min,60.8,132009,DB00013,Urokinase
,1906642,half-lives (area under the curve,"After scu-PA, urokinase antigen was cleared with half-lives (area under the curve in parentheses) of 6.9 min (74.8%), 26.5 min (23.6%), and 329.7 min (2.2%).",Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906642/),min,6.9,132010,DB00013,Urokinase
,1906642,half-lives (area under the curve,"After scu-PA, urokinase antigen was cleared with half-lives (area under the curve in parentheses) of 6.9 min (74.8%), 26.5 min (23.6%), and 329.7 min (2.2%).",Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906642/),min,26.5,132011,DB00013,Urokinase
,1906642,half-lives (area under the curve,"After scu-PA, urokinase antigen was cleared with half-lives (area under the curve in parentheses) of 6.9 min (74.8%), 26.5 min (23.6%), and 329.7 min (2.2%).",Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906642/),min,329.7,132012,DB00013,Urokinase
,1906642,half-disappearance times,"The half-disappearance times of fibrinolytic activity were 18 and 8 min in group I and II, respectively.",Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906642/),min,18,132013,DB00013,Urokinase
,1906642,half-disappearance times,"The half-disappearance times of fibrinolytic activity were 18 and 8 min in group I and II, respectively.",Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906642/),min,8,132014,DB00013,Urokinase
,15650519,half-life,The vitreous half-life was 19.4 hours.,Intraocular properties of urokinase-derived antiangiogenic A6 peptide in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650519/),h,19.4,136405,DB00013,Urokinase
,7649155,specific amidolytic activity,"The purified conjugate obtained has a lower specific amidolytic activity (72,000 U/mg) than unconjugated Cys-delta 125-pro-urikinase (240,000 U/mg) due to its higher molecular mass and has a similar fibrinolytic activity in a clot lysis test to that of delta 125-pro-urokinase.",Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649155/),[u] / [mg],"72,000",141623,DB00013,Urokinase
,7649155,specific amidolytic activity,"The purified conjugate obtained has a lower specific amidolytic activity (72,000 U/mg) than unconjugated Cys-delta 125-pro-urikinase (240,000 U/mg) due to its higher molecular mass and has a similar fibrinolytic activity in a clot lysis test to that of delta 125-pro-urokinase.",Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649155/),[u] / [mg],"240,000",141624,DB00013,Urokinase
,9584640,half-life (T1/2),"After intravitreal administration, the proRUK half-life (T1/2) was 7.9 +/- 1.44 h, with proRUK losing none of its enzymatic activity while in the vitreous body.",[Pharmacokinetics of recombinant pro-urokinase ocular dosage form]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584640/),h,7.9,141873,DB00013,Urokinase
,9584640,maximum accumulation,"In the sclera the maximum accumulation of proRUK is 10-15% (4-6 h after administration), in the vascular membrane 0.8% (4 h after administration).",[Pharmacokinetics of recombinant pro-urokinase ocular dosage form]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584640/),,10,141874,DB00013,Urokinase
,2121385,initial half-time,"After the end of the infusion, u-PA-related antigen disappeared from plasma in a biphasic manner with an initial half-time of 2.7 +/- 0.5 for rscu-PA, 24 +/- 1.2 for rscu-PA/MA-15C5, and 21 +/- 0.5 minutes for rscu-PA/MA-1C8 with corresponding plasma clearances of 340 +/- 40, 20 +/- 3, and 24 +/- 2 ml/min, respectively.",Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121385/),min,2.7,155683,DB00013,Urokinase
,2121385,initial half-time,"After the end of the infusion, u-PA-related antigen disappeared from plasma in a biphasic manner with an initial half-time of 2.7 +/- 0.5 for rscu-PA, 24 +/- 1.2 for rscu-PA/MA-15C5, and 21 +/- 0.5 minutes for rscu-PA/MA-1C8 with corresponding plasma clearances of 340 +/- 40, 20 +/- 3, and 24 +/- 2 ml/min, respectively.",Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121385/),min,24,155684,DB00013,Urokinase
,2121385,initial half-time,"After the end of the infusion, u-PA-related antigen disappeared from plasma in a biphasic manner with an initial half-time of 2.7 +/- 0.5 for rscu-PA, 24 +/- 1.2 for rscu-PA/MA-15C5, and 21 +/- 0.5 minutes for rscu-PA/MA-1C8 with corresponding plasma clearances of 340 +/- 40, 20 +/- 3, and 24 +/- 2 ml/min, respectively.",Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121385/),min,21,155685,DB00013,Urokinase
,2121385,plasma clearances,"After the end of the infusion, u-PA-related antigen disappeared from plasma in a biphasic manner with an initial half-time of 2.7 +/- 0.5 for rscu-PA, 24 +/- 1.2 for rscu-PA/MA-15C5, and 21 +/- 0.5 minutes for rscu-PA/MA-1C8 with corresponding plasma clearances of 340 +/- 40, 20 +/- 3, and 24 +/- 2 ml/min, respectively.",Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121385/),[ml] / [min],340,155686,DB00013,Urokinase
,2121385,plasma clearances,"After the end of the infusion, u-PA-related antigen disappeared from plasma in a biphasic manner with an initial half-time of 2.7 +/- 0.5 for rscu-PA, 24 +/- 1.2 for rscu-PA/MA-15C5, and 21 +/- 0.5 minutes for rscu-PA/MA-1C8 with corresponding plasma clearances of 340 +/- 40, 20 +/- 3, and 24 +/- 2 ml/min, respectively.",Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121385/),[ml] / [min],20,155687,DB00013,Urokinase
,2121385,plasma clearances,"After the end of the infusion, u-PA-related antigen disappeared from plasma in a biphasic manner with an initial half-time of 2.7 +/- 0.5 for rscu-PA, 24 +/- 1.2 for rscu-PA/MA-15C5, and 21 +/- 0.5 minutes for rscu-PA/MA-1C8 with corresponding plasma clearances of 340 +/- 40, 20 +/- 3, and 24 +/- 2 ml/min, respectively.",Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2121385/),[ml] / [min],24,155688,DB00013,Urokinase
,8236142,clearance,The clearance of saruplase ranged from 310 to 862 ml/min and the apparent volume of distribution of the central compartment was about 8 1.,"Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236142/),[ml] / [min],310 to 862,165156,DB00013,Urokinase
,8236142,apparent volume of distribution of the central compartment,The clearance of saruplase ranged from 310 to 862 ml/min and the apparent volume of distribution of the central compartment was about 8 1.,"Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236142/),1,8,165157,DB00013,Urokinase
,15176647,Time to peak plasma concentration,Time to peak plasma concentration was similar (0.5-2.1 h) in all dosage groups.,"Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176647/),h,0.5-2.1,176616,DB00013,Urokinase
,15176647,Cmax,"Mean Cmax ranged from 454-10,333 ng/ml and mean AUC(0-inf) from 1,690-43,371 ng x h/ml after the 15 and 300 mg single doses, respectively.","Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176647/),[ng] / [ml],"454-10,333",176617,DB00013,Urokinase
,15176647,AUC(0-inf),"Mean Cmax ranged from 454-10,333 ng/ml and mean AUC(0-inf) from 1,690-43,371 ng x h/ml after the 15 and 300 mg single doses, respectively.","Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176647/),[h·ng] / [ml],"1,690-43,371",176618,DB00013,Urokinase
,15176647,Terminal t(1/2),"Terminal t(1/2) was 1.4-1.8 h, and there was no evidence of unexpected drug accumulation.","Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176647/),h,1.4-1.8,176619,DB00013,Urokinase
,15176647,Urinary excretion,"Urinary excretion of unchanged A6 was 94.6% (SD 20.7) after the 300 mg single dose (0-24 h collection), and 78.4% (SD 13.0) after the 150 mg repeated dose (0-12 h collection).","Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176647/),%,94.6,176620,DB00013,Urokinase
,15176647,Urinary excretion,"Urinary excretion of unchanged A6 was 94.6% (SD 20.7) after the 300 mg single dose (0-24 h collection), and 78.4% (SD 13.0) after the 150 mg repeated dose (0-12 h collection).","Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176647/),%,78.4,176621,DB00013,Urokinase
,16023182,Time to peak plasma level,Time to peak plasma level of A6 was 1-2 h.,"A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023182/),h,1-2,184741,DB00013,Urokinase
,16023182,half-life,The half-life of A6 was approximately 2 h.,"A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023182/),h,2,184742,DB00013,Urokinase
,28714475,Kd,"In accordance with this strategy, we developed an easily synthesized albumin-binding ligand based on a peptide-fatty acid chimera that has a high affinity for human albumin (Kd=39 nM).",Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28714475/),nM,39,189734,DB00013,Urokinase
,28714475,half-life,"Conjugation to a peptide factor XII inhibitor developed for anti-thrombotic therapy extends the half-life from 13 minutes to over five hours, inhibiting coagulation for eight hours in rabbits.",Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28714475/),min,13,189735,DB00013,Urokinase
,28714475,half-life,"Conjugation to a peptide factor XII inhibitor developed for anti-thrombotic therapy extends the half-life from 13 minutes to over five hours, inhibiting coagulation for eight hours in rabbits.",Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28714475/),h,over,189736,DB00013,Urokinase
,28714475,half-life,"Conjugation to a peptide factor XII inhibitor developed for anti-thrombotic therapy extends the half-life from 13 minutes to over five hours, inhibiting coagulation for eight hours in rabbits.",Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28714475/),h,five,189737,DB00013,Urokinase
,505403,half-life,"The plasma clearance of 125I-UK in rabbits was described by a biexponential curve within six hours with a half-life of 8 minutes, 2.3 hours, respectively.",Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/505403/),min,8,203096,DB00013,Urokinase
,505403,half-life,"The plasma clearance of 125I-UK in rabbits was described by a biexponential curve within six hours with a half-life of 8 minutes, 2.3 hours, respectively.",Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/505403/),h,2.3,203097,DB00013,Urokinase
,505403,radioactivity,"The radioactivity in the liver and kidneys 15 minutes after iv injection with 125I-UK was 9.6% and 14.0% of the radioactivity injected, respectively.",Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/505403/),%,9,203098,DB00013,Urokinase
,505403,radioactivity,"The radioactivity in the liver and kidneys 15 minutes after iv injection with 125I-UK was 9.6% and 14.0% of the radioactivity injected, respectively.",Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/505403/),%,14.,203099,DB00013,Urokinase
,9216639,maximal concentration,Pharmacokinetic studies in mice revealed that the maximal concentration of cytogenin in plasma after a single 100 mg/kg oral dose of the compound was 32 microM.,"Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9216639/),μM,32,211133,DB00013,Urokinase
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,380,216064,DB00013,Urokinase
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,78,216065,DB00013,Urokinase
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),mg,0.19,216066,DB00013,Urokinase
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),mg,0.82,216067,DB00013,Urokinase
,1571545,maximal rate of lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,60,216068,DB00013,Urokinase
,1571545,maximal rate of lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,220,216069,DB00013,Urokinase
,1571545,maximal lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),,1,216070,DB00013,Urokinase
,1571545,maximal lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),,0,216071,DB00013,Urokinase
,1571545,initial half-life,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),min,3.3,216072,DB00013,Urokinase
,1571545,initial half-life,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),min,13,216073,DB00013,Urokinase
,1571545,plasma clearances,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),[ml] / [min],340,216074,DB00013,Urokinase
,1571545,plasma clearances,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),[ml] / [min],10,216075,DB00013,Urokinase
,1571545,plasma clearances,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),[ml] / [min],37,216076,DB00013,Urokinase
,11477374,catabolic half-life,The catabolic half-life of AST-I (2.01 +/- 0.19 days) was significantly less than that of AST-II (2.62 +/- 0.20 days).,Metabolism of rabbit angiostatin glycoforms I and II in rabbits: angiostatin-I leaves the intravascular space faster and appears to have greater anti-angiogenic activity than angiostatin-II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477374/),d,2.01,236153,DB00013,Urokinase
,11477374,catabolic half-life,The catabolic half-life of AST-I (2.01 +/- 0.19 days) was significantly less than that of AST-II (2.62 +/- 0.20 days).,Metabolism of rabbit angiostatin glycoforms I and II in rabbits: angiostatin-I leaves the intravascular space faster and appears to have greater anti-angiogenic activity than angiostatin-II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477374/),d,2.62,236154,DB00013,Urokinase
,7534946,steady state plasma concentrations,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),[μg] / [ml],2.75,240530,DB00013,Urokinase
,7534946,steady state plasma concentrations,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),[μg] / [ml],2.50,240531,DB00013,Urokinase
,7534946,t1/2 lambda 1,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),min,9.1,240532,DB00013,Urokinase
,7534946,t1/2 lambda 1,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),min,7.8,240533,DB00013,Urokinase
,7534946,t1/2 lambda 2,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),h,1.2,240534,DB00013,Urokinase
,7534946,t1/2 lambda 2,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),h,1.9,240535,DB00013,Urokinase
,7534946,total clearance,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),[ml] / [min],393,240536,DB00013,Urokinase
,7534946,total clearance,"For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 microgram, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 micrograms/ml (mean +/- standard deviation) and were reached within 20 min, t1/2 lambda 1 was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t1/2 lambda 2 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min.","Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534946/),[ml] / [min],427,240537,DB00013,Urokinase
,10500311,"maximum concentration (C(max,)","The maximum concentration (C(max,), mean +/- SD) of total u-PA activity was 2.2 +/- 0.3 microg/mL after standard therapy, 16.3 +/- 3.9 microg/mL after single bolus, and 8.2 +/- 1.6 ug/mL after split bolus.","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [ml],2.2,244446,DB00013,Urokinase
,10500311,"maximum concentration (C(max,)","The maximum concentration (C(max,), mean +/- SD) of total u-PA activity was 2.2 +/- 0.3 microg/mL after standard therapy, 16.3 +/- 3.9 microg/mL after single bolus, and 8.2 +/- 1.6 ug/mL after split bolus.","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [ml],16.3,244447,DB00013,Urokinase
,10500311,"maximum concentration (C(max,)","The maximum concentration (C(max,), mean +/- SD) of total u-PA activity was 2.2 +/- 0.3 microg/mL after standard therapy, 16.3 +/- 3.9 microg/mL after single bolus, and 8.2 +/- 1.6 ug/mL after split bolus.","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[ug] / [ml],8.2,244448,DB00013,Urokinase
,10500311,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) values of total u-PA activity were 1.7 +/- 0.1 microg/mL*h (standard therapy), 4.0 +/- 0.9 microg/mL*h (bolus), and 3.0 +/- 0.7 microg/mL*h (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [h·ml],1.7,244449,DB00013,Urokinase
,10500311,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) values of total u-PA activity were 1.7 +/- 0.1 microg/mL*h (standard therapy), 4.0 +/- 0.9 microg/mL*h (bolus), and 3.0 +/- 0.7 microg/mL*h (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [h·ml],4.0,244450,DB00013,Urokinase
,10500311,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) values of total u-PA activity were 1.7 +/- 0.1 microg/mL*h (standard therapy), 4.0 +/- 0.9 microg/mL*h (bolus), and 3.0 +/- 0.7 microg/mL*h (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [h·ml],3.0,244451,DB00013,Urokinase
,10500311,initial half-lives (t(1/2) alpha),"The dominant initial half-lives (t(1/2) alpha) were 7.1 +/- 1.1 minutes (standard), 8.8 +/- 0.8 minutes (bolus), and 5.1 +/- 2.1 minutes (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),min,7.1,244452,DB00013,Urokinase
,10500311,initial half-lives (t(1/2) alpha),"The dominant initial half-lives (t(1/2) alpha) were 7.1 +/- 1.1 minutes (standard), 8.8 +/- 0.8 minutes (bolus), and 5.1 +/- 2.1 minutes (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),min,8.8,244453,DB00013,Urokinase
,10500311,initial half-lives (t(1/2) alpha),"The dominant initial half-lives (t(1/2) alpha) were 7.1 +/- 1.1 minutes (standard), 8.8 +/- 0.8 minutes (bolus), and 5.1 +/- 2.1 minutes (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),min,5.1,244454,DB00013,Urokinase
,10500311,Maximum plasma concentrations,"Maximum plasma concentrations of of tcu-PA activity were observed at 5.2 +/- 7 minutes (standard), 21 +/- 10 minutes (bolus), and 42 +/- 2 minutes (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),min,5.2,244455,DB00013,Urokinase
,10500311,Maximum plasma concentrations,"Maximum plasma concentrations of of tcu-PA activity were observed at 5.2 +/- 7 minutes (standard), 21 +/- 10 minutes (bolus), and 42 +/- 2 minutes (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),min,21,244456,DB00013,Urokinase
,10500311,Maximum plasma concentrations,"Maximum plasma concentrations of of tcu-PA activity were observed at 5.2 +/- 7 minutes (standard), 21 +/- 10 minutes (bolus), and 42 +/- 2 minutes (split bolus).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),min,42,244457,DB00013,Urokinase
,10500311,C(max),"C(max) was lowest after standard therapy (0.6 +/- 0.3 microg/mL), highest after bolus (4.2 +/- 2.2 microg/mL), and approximately twice as high as standard therapy after split bolus (1. 3 +/- 0.8 microg/mL).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [ml],0.6,244458,DB00013,Urokinase
,10500311,C(max),"C(max) was lowest after standard therapy (0.6 +/- 0.3 microg/mL), highest after bolus (4.2 +/- 2.2 microg/mL), and approximately twice as high as standard therapy after split bolus (1. 3 +/- 0.8 microg/mL).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [ml],4.2,244459,DB00013,Urokinase
,10500311,C(max),"C(max) was lowest after standard therapy (0.6 +/- 0.3 microg/mL), highest after bolus (4.2 +/- 2.2 microg/mL), and approximately twice as high as standard therapy after split bolus (1. 3 +/- 0.8 microg/mL).","Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500311/),[μg] / [ml],1. 3,244460,DB00013,Urokinase
,21851064,IC(50),"Synthesis of an analogue of 1, namely, 2 (IPR-9), and 3 led to breast MDA-MB-231 invasion, migration and adhesion assays with IC(50) near 30 μM.","Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851064/),μM,30,250518,DB00013,Urokinase
,21851064,IC(50),Both compounds blocked angiogenesis with IC(50) of 3 μM.,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851064/),μM,3,250519,DB00013,Urokinase
,21851064,IC(50),Compounds 2 and 3 inhibited cell growth with IC(50) of 6 and 18 μM and induced apoptosis.,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851064/),μM,6,250520,DB00013,Urokinase
,21851064,IC(50),Compounds 2 and 3 inhibited cell growth with IC(50) of 6 and 18 μM and induced apoptosis.,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851064/),μM,18,250521,DB00013,Urokinase
,21851064,half-life,Compound 3 administered orally reached peak concentration of nearly 40 μM with a half-life of about 2 h.,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21851064/),h,2,250522,DB00013,Urokinase
,4008166,labeling efficiency,"The labeling efficiency was 91.7% for the H-UK, and 90.4% for the L-UK, respectively.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),%,91.7,251089,DB00013,Urokinase
,4008166,labeling efficiency,"The labeling efficiency was 91.7% for the H-UK, and 90.4% for the L-UK, respectively.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),%,90.4,251090,DB00013,Urokinase
,4008166,half-life,Studies on the in vivo behavior of the 67Ga labeled UK in rabbits showed a very rapid blood clearance with half-life of 4 min (67Ga-DF-L-UK) to 8 min (67Ga-DF-H-UK).,In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),min,4,251091,DB00013,Urokinase
,4008166,half-life,Studies on the in vivo behavior of the 67Ga labeled UK in rabbits showed a very rapid blood clearance with half-life of 4 min (67Ga-DF-L-UK) to 8 min (67Ga-DF-H-UK).,In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),min,8,251092,DB00013,Urokinase
,4008166,activity ratios,"Studies carried out in rabbits with induced thrombi in the femoral vein showed thrombus-to-blood 67Ga-DF-UK activity ratios, 2h after injection, of 2.00-3.08 for the H-UK, and 0.84-1.65 for the L-UK, respectively, with thrombi aged 4 to 3 days.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),,2.00-3.08,251093,DB00013,Urokinase
,4008166,activity ratios,"Studies carried out in rabbits with induced thrombi in the femoral vein showed thrombus-to-blood 67Ga-DF-UK activity ratios, 2h after injection, of 2.00-3.08 for the H-UK, and 0.84-1.65 for the L-UK, respectively, with thrombi aged 4 to 3 days.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),,0.84-1.65,251094,DB00013,Urokinase
,25278451,MTD,The MTD was determined as 400 mg once daily.,"A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25278451/),mg,400,264610,DB00013,Urokinase
,3137685,peak plasma concentrations,Mean peak plasma concentrations at the end of infusion were 4.7 micrograms/ml for hPA(B) and 4.6 micrograms/ml for mtPA.,Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),[μg] / [ml],4.7,271301,DB00013,Urokinase
,3137685,peak plasma concentrations,Mean peak plasma concentrations at the end of infusion were 4.7 micrograms/ml for hPA(B) and 4.6 micrograms/ml for mtPA.,Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),[μg] / [ml],4.6,271302,DB00013,Urokinase
,3137685,t 1/2 (lambda 1),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,2,271303,DB00013,Urokinase
,3137685,t 1/2 (lambda 2),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,58,271304,DB00013,Urokinase
,3137685,t 1/2 (lambda 1),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,2.2,271305,DB00013,Urokinase
,3137685,t 1/2 (lambda 2),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,61,271306,DB00013,Urokinase
